MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding Metabolic syndrome?
MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding Metabolic syndrome?
In 1980, there was the first description of patients with nonalcoholic steatohepatitis (NASH), most of whom were overweight and had type 2 diabetes. In the following years, there has been a growing appreciation that metabolic dysfunction underpins this liver disease, and metabolic dysfunction also contributes to the increased risk of extrahepatic complications, manifest in nonalcoholic fatty liver disease (NAFLD) as a multisystem disease. In 2020 & 2023, it was proposed that NAFLD should be renamed and reclassified as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), respectively. Despite subtle differences between MAFLD or MASLD, there is excellent congruence between NAFLD, MAFLD or MASLD definitions, and affected patients usually meet criteria for all. The following is a perspective of the authors’ views as to the challenges and advantages of the new fatty liver disease terminology and classification.
Insulin resistance, MAFLD, MASLD, NAFLD, cardiovascular disease, extrahepatic complications, metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease, metabolic syndrome, nonalcoholic fatty liver disease
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Targher, Giovanni
416558bd-6d5a-4c61-9c2c-637acfbdb039
26 February 2024
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Targher, Giovanni
416558bd-6d5a-4c61-9c2c-637acfbdb039
Byrne, Christopher D. and Targher, Giovanni
(2024)
MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding Metabolic syndrome?
Metabolism and Target Organ Damage, 4 (10).
(doi:10.20517/mtod.2024.06).
Abstract
In 1980, there was the first description of patients with nonalcoholic steatohepatitis (NASH), most of whom were overweight and had type 2 diabetes. In the following years, there has been a growing appreciation that metabolic dysfunction underpins this liver disease, and metabolic dysfunction also contributes to the increased risk of extrahepatic complications, manifest in nonalcoholic fatty liver disease (NAFLD) as a multisystem disease. In 2020 & 2023, it was proposed that NAFLD should be renamed and reclassified as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), respectively. Despite subtle differences between MAFLD or MASLD, there is excellent congruence between NAFLD, MAFLD or MASLD definitions, and affected patients usually meet criteria for all. The following is a perspective of the authors’ views as to the challenges and advantages of the new fatty liver disease terminology and classification.
Text
Revision-MTOD-2024-6-Manuscript-File.v3_cb
- Accepted Manuscript
Text
mtod4006_down (1)
- Version of Record
More information
Accepted/In Press date: 20 February 2024
e-pub ahead of print date: 24 February 2024
Published date: 26 February 2024
Keywords:
Insulin resistance, MAFLD, MASLD, NAFLD, cardiovascular disease, extrahepatic complications, metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease, metabolic syndrome, nonalcoholic fatty liver disease
Identifiers
Local EPrints ID: 487448
URI: http://eprints.soton.ac.uk/id/eprint/487448
ISSN: 1073-0842
PURE UUID: 7d76a34d-2c25-40a1-b581-316087e103d5
Catalogue record
Date deposited: 20 Feb 2024 18:03
Last modified: 10 Aug 2024 01:36
Export record
Altmetrics
Contributors
Author:
Giovanni Targher
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
